PER · ASX

Percheron Therapeutics Limited (ASX:PER)

AU$0.007

 0.0 (0.0%)
ASX:Live
20/12/2024 04:10:10 PM
Recent Earnings upgrade HALO Ords HALO Consensus Value GROWTH AUS Fakey Shakey - Long +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PER Overview

PER Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About PER

Website

Percheron Therapeutics Limited

Telephone

61.3.9827.8999

Address

Level 30 35 Collins Street Collins Place Melbourne, Victoria (VIC) 3000

Description

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.

PER Price Chart

Key Stats

Market Cap

AU$7.61M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.14

Trade Value (12mth)

AU$31,256.00

1 week

-88.14%

1 month

-91.03%

YTD

-88.52%

1 year

-87.27%

All time high

1.85

Key Fundamentals

EPS 3 yr Growth

-9.40%

EBITDA Margin

N/A

Operating Cashflow

-$10m

Free Cash Flow Return

-104.40%

ROIC

-123.00%

Interest Coverage

-4,107.90

Quick Ratio

2.80

Other Data

Shares on Issue (Fully Dilluted)

902m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PER Announcements

Latest Announcements

Date Announcements

19 December 24

Change in substantial holding

×

Change in substantial holding

18 December 24

Topline Six-Month Results From Phase IIb Study of Avicursen

×

Topline Six-Month Results From Phase IIb Study of Avicursen

16 December 24

Trading Halt

×

Trading Halt

03 December 24

Reorganisation of US Quoted Securities

×

Reorganisation of US Quoted Securities

02 December 24

Resignation of Joint Company Secretary

×

Resignation of Joint Company Secretary

02 December 24

Clinical Trial Update

×

Clinical Trial Update

29 November 24

Notification regarding unquoted securities - PER

×

Notification regarding unquoted securities - PER

28 November 24

Change of Director's Interest Notice - Dr James Garner

×

Change of Director's Interest Notice - Dr James Garner

27 November 24

Notice under S708A

×

Notice under S708A

26 November 24

Application for quotation of securities - PER

×

Application for quotation of securities - PER

25 November 24

Notification regarding unquoted securities - PER

×

Notification regarding unquoted securities - PER

25 November 24

Change of Director's Interest Notice Dr James Garner

×

Change of Director's Interest Notice Dr James Garner

25 November 24

Change of Director's Interest Notice - Dr Ben Gil Price

×

Change of Director's Interest Notice - Dr Ben Gil Price

21 November 24

Withdrawal of Resolutions from the Annual General Meeting

×

Withdrawal of Resolutions from the Annual General Meeting

21 November 24

Annual General Meeting - Chair's Address

×

Annual General Meeting - Chair's Address

21 November 24

Annual General Meeting Management Presentation

×

Annual General Meeting Management Presentation

21 November 24

Results of the Annual General Meeting

×

Results of the Annual General Meeting

21 November 24

Proposed issue of securities - PER

×

Proposed issue of securities - PER

21 November 24

Proposed issue of securities - PER

×

Proposed issue of securities - PER

15 November 24

Change in substantial holding

×

Change in substantial holding

14 November 24

Application for quotation of securities - PER

×

Application for quotation of securities - PER

14 November 24

Change of Director's Interest Notice - Dr James Garner

×

Change of Director's Interest Notice - Dr James Garner

13 November 24

Results of Share Purchase Plan

×

Results of Share Purchase Plan

31 October 24

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

28 October 24

Share Purchase Plan Offer Booklet

×

Share Purchase Plan Offer Booklet

PER Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 38.3 -84.8 20.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.0 -96.7 21.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -23.9 -31.1 -20.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.01 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 217.1 -52.9 -30.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 634 669 881 Lock Lock Lock
Basic m Lock Lock Lock Lock 634 669 881 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 8 13 15 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.6 -6.7 16.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -8 -13 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 12.3 -76.1 -11.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -8 -13 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 12.3 -75.3 -11.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -8 -13 -14 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -11 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.9 -95.8 -4.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -8 -8 -10 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 21 0 11 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -8 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.7 -4.8 -23.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 19 11 12 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 22 13 15 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -19 -11 -12 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 3 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 21 10 9 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 21 10 9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 257.3 -52.9 -6.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -25.9 -88.6 -82.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.5 -114.1 -127.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -55.5 -84.8 -152.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -42.7 -72.7 -123.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -57.3 -52.1 -104.4 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -631.7 -1,624.9 -4,107.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.5 0.8 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -89.9 -108.5 -126.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 19.1 4.5 2.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 19.1 4.5 2.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.6 86.4 82.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -672.4 -289.8 -196.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -25.9 -88.6 -82.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.3 1.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.5 -114.1 -127.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -27.5 -114.1 -127.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 999.2 2,596.0 10,928.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -999.2 -2,596.0 -10,928.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PER Shortsell

Frequently Asked Questions

The current share price of Percheron Therapeutics Limited (PER:ASX) is AU$0.007.
The 52-week high share price for Percheron Therapeutics Limited (PER:ASX) is AU$0.14.
The 52-week low share price for Percheron Therapeutics Limited (PER:ASX)? is AU$0.00.
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
Percheron Therapeutics Limited (PER:ASX) has a franking level of 0.0%.
Percheron Therapeutics Limited (PER:ASX) is classified in the Healthcare.
The current P/E ratio for Percheron Therapeutics Limited (PER:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.